Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) insider Pierre Sargis Sayad sold 12,000 shares of the firm's stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the transaction, the insider owned 9,519 shares in the company, valued at $115,941.42. The trade was a 55.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Adherex Technologies Stock Up 0.7%
FENC opened at $12.35 on Tuesday. Adherex Technologies Inc. has a 52-week low of $5.65 and a 52-week high of $13.25. The company has a 50 day moving average of $10.87 and a two-hundred day moving average of $8.95. The company has a market cap of $432.99 million, a P/E ratio of -95.00 and a beta of 1.09.
Adherex Technologies (NASDAQ:FENC - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. Adherex Technologies had a negative net margin of 6.09% and a negative return on equity of 5.71%. The firm had revenue of $17.87 million during the quarter, compared to analysts' expectations of $16.21 million. Research analysts anticipate that Adherex Technologies Inc. will post 0.29 earnings per share for the current year.
Institutional Investors Weigh In On Adherex Technologies
An institutional investor recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,897 shares of the company's stock, valued at approximately $66,000. Institutional investors and hedge funds own 55.51% of the company's stock.
Analyst Ratings Changes
A number of research firms have weighed in on FENC. HC Wainwright upped their price target on Adherex Technologies from $13.00 to $16.00 and gave the stock a "buy" rating in a report on Friday, May 22nd. Zacks Research raised shares of Adherex Technologies from a "strong sell" rating to a "hold" rating in a research report on Monday, May 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Adherex Technologies in a research note on Friday, July 17th. Wall Street Zen raised shares of Adherex Technologies from a "hold" rating to a "strong-buy" rating in a research note on Saturday, May 16th. Finally, Wedbush boosted their price objective on shares of Adherex Technologies from $13.00 to $16.00 and gave the stock an "outperform" rating in a report on Wednesday, August 12th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $17.00.
View Our Latest Stock Analysis on Adherex Technologies
About Adherex Technologies
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
